CN104258241A - 一种防治老年痴呆的保健品 - Google Patents
一种防治老年痴呆的保健品 Download PDFInfo
- Publication number
- CN104258241A CN104258241A CN201410506188.7A CN201410506188A CN104258241A CN 104258241 A CN104258241 A CN 104258241A CN 201410506188 A CN201410506188 A CN 201410506188A CN 104258241 A CN104258241 A CN 104258241A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- senile dementia
- extract
- health product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 57
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 39
- 230000036541 health Effects 0.000 title claims abstract description 21
- 239000000284 extract Substances 0.000 claims abstract description 37
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 28
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 23
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 20
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 17
- 241000222336 Ganoderma Species 0.000 claims abstract description 16
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960000304 folic acid Drugs 0.000 claims abstract description 14
- 235000019152 folic acid Nutrition 0.000 claims abstract description 14
- 239000011724 folic acid Substances 0.000 claims abstract description 14
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 12
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 11
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 11
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 11
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 11
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 11
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 11
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 11
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 11
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 11
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 11
- 239000011718 vitamin C Substances 0.000 claims abstract description 11
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 11
- 229940046009 vitamin E Drugs 0.000 claims abstract description 11
- 239000011709 vitamin E Substances 0.000 claims abstract description 11
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 10
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 10
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 10
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 10
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 241000218628 Ginkgo Species 0.000 claims description 16
- 235000011201 Ginkgo Nutrition 0.000 claims description 16
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 16
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 11
- 241000361919 Metaphire sieboldi Species 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 9
- 238000000465 moulding Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 22
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 239000009429 Ginkgo biloba extract Substances 0.000 abstract 1
- 241000243684 Lumbricus Species 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229940068052 ginkgo biloba extract Drugs 0.000 abstract 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 abstract 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 description 31
- 210000004958 brain cell Anatomy 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 230000006870 function Effects 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 201000010099 disease Diseases 0.000 description 13
- 230000015654 memory Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 206010012289 Dementia Diseases 0.000 description 8
- 230000002490 cerebral effect Effects 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 239000002858 neurotransmitter agent Substances 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000036770 blood supply Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000916 dilatatory effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940124277 aminobutyric acid Drugs 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 150000001669 calcium Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 229930182486 flavonoid glycoside Natural products 0.000 description 2
- 150000007955 flavonoid glycosides Chemical class 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- -1 methyl compound Chemical class 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 229940046001 vitamin b complex Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 206010004954 Birth trauma Diseases 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000019743 Cranial nerve injury Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 241000237636 Pheretima Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- UNWAHVGSROASNT-HXNJGWPRSA-N amarolide Chemical compound C[C@H]1C(=O)[C@@H](O)[C@@H]2[C@@]3(C)C(=O)[C@@H](O)C[C@@H](C)[C@@H]3C[C@@H]3[C@@]2(C)[C@H]1CC(=O)O3 UNWAHVGSROASNT-HXNJGWPRSA-N 0.000 description 1
- UNWAHVGSROASNT-UHFFFAOYSA-N amarolide Natural products CC1C(=O)C(O)C2C3(C)C(=O)C(O)CC(C)C3CC3C2(C)C1CC(=O)O3 UNWAHVGSROASNT-UHFFFAOYSA-N 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000008084 cerebral blood perfusion Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930184727 ginkgolide Natural products 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000009209 sensory transmission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HSTCACQRSLZQHZ-UHFFFAOYSA-N shinjulactone H Natural products CC1CC(O)C(=O)C2(C)C1CC3OC(=O)CC4C(C)C(O)C(=O)C2C34C HSTCACQRSLZQHZ-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000003563 vegetarian diet Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明的目的在于提供一种防治老年痴呆的保健品，其配方中各组成部分的质量配比是：益智仁粉3~7份、地龙蛋白8~12份、银杏叶提取物6~14份、灵芝提取物8~12份、肉桂提取物3~7份、磷脂酰丝氨酸3~7份、γ-氨基丁酸12~18份、L-色氨酸3~7份、烟酸1~3份、维生素C3~7份、维生素E2~6份、维生素B6 0.3~0.7份、维生素B12 0.1~0.4份、叶酸0.005~0.015份；本发明的最终成型药剂剂型为：粉剂、片剂、胶囊。本发明不但是由纯植物或提取物组合而成，无毒无副作用，而且配方简单、成本低廉，效果佳。
Description
技术领域
本发明涉及保健品领域，尤其是一种防治老年痴呆的保健品。
背景技术
老年痴呆为阿尔茨海默病（AD）是一种起病隐匿的进行性发展的神经系统退行性疾病。临床上以记忆障碍、失语、失用、失认、视空间技能损害、执行功能障碍以及人格和行为改变等全面性痴呆表现为特征，病因迄今未明。65岁以前发病者，称早老性痴呆；65岁以后发病者称老年性痴呆。
虽然阿兹海默症在每个病患都不相同，仍有许多共同的症状。早期症状常被误认为是“年纪大了”的忧虑，或是压力的一种表现，疾病初期最常见的症状是难以记住最近发生的事。当怀疑为阿兹海默症时，通常借由行为评估以及认知测试来确认诊断，可能的话接着会做神经影像检查辅助诊断。随着疾病进展，症状将会包括谵妄、易怒、具攻击性、情绪起伏不定、丧失长期记忆等，当病患功能下降时，会从家庭和社会的社交关系中退出，随着身体功能逐渐丧失，最终导致病患死亡。因为疾病在每个病患均不相同，因此很难预测患者的预后。阿兹海默症的发展时间无法预测，时间长短也非常多变，并且可能经年未被发现直到疾病显而易见，平均而言，阿兹海默症确诊之后的存活期约有七年，确诊之后存活超过十四年的病患少于3份。
目前仍不清楚阿兹海默症的成因及疾病进程，研究显示阿兹海默症与大脑中的老年斑块和神经纤维纠结有关。目前的治疗仅能帮助缓解疾病的症状，并没有能够停止或是反转阿兹海默症病程的治疗方法。截至2012年为止，已有超过1000个临床试验研究如何治疗阿兹海默症，然而这些研究是否能找到有效的治疗方法仍是未知数。
由于阿兹海默症是无法治愈的退化性疾病，病患终需依赖其他人协助及照顾，主要的照护者通常是病患的伴侣或是亲近的家属。然而照护阿兹海默症病患会对照护者产生非常大的负担，对照护者的人生各方面都造成压力，包括其社交、精神、体能和经济都会受到影响。在发达国家中，阿兹海默症是社会中花费最高的疾病之一。
发明内容
本发明的目的在于提供一种防治老年痴呆的保健品，其能够有效的防止老年痴呆症的出现。
所述的一种防治老年痴呆的保健品，其配方中各组成部分的质量配比是：益智仁粉3~7份、地龙蛋白8~12份、银杏叶提取物6~14份、灵芝提取物8~12份、肉桂提取物3~7份、磷脂酰丝氨酸3~7份、γ-氨基丁酸12~18份、L-色氨酸3~7份、烟酸1~3份、维生素C 3~7份、维生素E 2~6份、维生素B6 0.3~0.7份、维生素B12 0.1~0.4份、叶酸 0.005~0.015份；本发明的最终成型药剂剂型为：粉剂、片剂、胶囊。
所述的一种防治老年痴呆的保健品，其配方中各组成部分的最佳质量配比是：益智仁粉5份、地龙蛋白10份、银杏叶提取物10份、灵芝提取物10份、肉桂提取物5份、磷脂酰丝氨酸5份、γ-氨基丁酸15份、L-色氨酸5份、烟酸2份、维生素C 5份、维生素E 4份、维生素B6 0.5份、维生素B12 0.25份、叶酸 0.01份。
益智仁粉：有科研报告指出, 益智仁粉可提高能量代谢, 促进体内钙类物质及核苷酸的合成．动物实验表明：用益智仁粉可以提高小鼠脑肾上腺素递质、脑多巴胺、核苷酸及血浆核苷酸的含量, 并有增加记忆及增强免疫的功能．结合中药功效益智仁粉有补肾益脾，健脑生髓的作用。
地龙蛋白：地龙蛋白具有抗凝和加速纤维蛋白溶解双重作用，从而抑制血栓形成，促进血栓溶解，对修复、调节血管内皮细胞，降低血液黏度，血浆黏度，改善微循环，增加脑血流供应有明显作用，具有防治动脉硬化、脑血栓的作用。同时，地龙蛋白还能够为大脑细胞提供营养和能量，改变大脑的缺血缺氧状况，能够营养正常的细胞，修复受损的细胞，激活频死的细胞，完善大脑记忆，提高生活能力，有效缓解老年痴呆病症。
银杏叶提取物：银杏叶中含有天然活性黄酮及苦内酯等与人体健康有益的多种成份，具有溶解胆固醇，扩张血管的作用，对改善脑功能障碍、动脉硬化、高血压、眩晕、耳鸣、头痛、老年痴呆、记忆力减退等有明显效果。其防病、治病、健身的价值在明代李时珍的《本草纲目》中早有记载。经国家卫生部门检测证明：饮用银杏茶可明显降低血清胆固醇、甘油三脂和低密度血脂蛋白，减少体内贮存脂肪的作用。对于高血脂的调节、高血压和冠心病等心脑血管系统疾病患者辅助性防治有良好的功效，是预防治疗老年痴呆的理想饮品。大量的药理实验结果显示，银杏叶中有重要药理活性作用的成分有两大类：银杏黄酮甙和银杏苦内酯。银杏黄酮甙已被证实能有效地对抗和消除自由基。银杏叶可用于预防和医治早期老年痴呆症患者，尤对帮助恢复和改善记忆力作用明显。
灵芝提取物：老年痴呆症，由多种病因造成。如脑血管硬化，血脂沉积于血管，管径变细，心搏功能下降，大脑细胞得不到足够大氧和营养，细胞合成蛋白质能力下降，大脑严重萎缩，自由基数量增加，大脑细胞膜的脂质过氧化水平提高，脂褐质素在大脑皮层中的积累增多等。此外，高血脂、糖尿病、肾炎、脑血栓、脑外伤、新陈代谢障碍等，也能引起大脑功能减退或产生严重障碍，促使老年痴呆症的发生。灵芝能消除老年痴呆症的多种形成因素，能提高机体蛋白质、DNA、RNA的合成能力，消除自由基，解除自由基对大脑组织的破坏作用，能抑制大脑组织的脂质过氧化，抑制褐质素的产生，提高血红蛋白供氧能力，降低机体无效氧的消耗，加速血液循环，改善大脑供氧和营养状态，使大脑处于良好的生理状态。灵芝能消除老年痴呆症的多种形成因素，能提高机体蛋白质、DNA、RNA的合成能力，消除自由基，解除自由基对大脑组织的破坏作用，能抑制大脑组织的脂质过氧化，抑制褐质素的产生，提高血红蛋白供氧能力，降低机体无效氧的消耗，加速血液循环，改善大脑供氧和营养状态，使大脑处于良好的生理状态。服用灵芝提取物可增加血红蛋白生成，降低血脂从而软化血管，促进血液循环，增强脑血流灌注，增强脑神经元细胞活力，抗氧自由基，调整全身机能活力，从而阻止病情的发展，延缓脑功能衰退。临床结果表明，服用灵芝提取物后，轻、中度痴呆疗效较重度痴呆疗效高，尤其是轻度痴呆疗效最为显著。同时，在治疗后血红蛋白显著增高，血脂总胆固醇及甘油三脂显著下降。
肉桂提取物：2009年的一项研究发现，肉桂可以透过空气能提高人的警觉性。2013年发表在《阿尔茨海默氏病杂志》（the Journal of Alzheimer’s Diseas）上的一篇研究报告指出，肉桂化合物也有助于预防老年痴呆症。肉桂有助于防止老年痴呆症的发生。肉桂可加入食物和饮料中，每天半茶匙至1茶匙(250毫克至500毫克)可有效防止老年痴呆。
磷脂酰丝氨酸：功能主要是改善神经细胞功能，调节神经脉冲的传导，增进大脑记忆功能，由于其具有很强的亲脂性，吸收后能够迅速通过血脑屏障进入大脑，起到舒缓血管平滑肌细胞，增加脑部供血的作用。在本方中主要是改善神经细胞功能，调节神经脉冲的传导，增进大脑记忆力，由于其具有很强的亲脂性，吸收后能够迅速通过血脑屏障进入大脑，起到舒缓血管平滑肌细胞，增加脑部供血的作用。
γ-氨基丁酸：1、能促进脑的活化性，健脑益智，抗癫痫，促进睡眠，延缓脑衰老，能补充人体抑制性神经递质，具有良好的降血压功效。γ-氨基丁酸主要是能进入脑内三羧酸循环，促进脑细胞代谢，同时还能提高葡萄糖代谢时葡萄糖磷酸酯酶的活性，增加乙酰胆碱的生成，扩张血管增加血流量，并降低血氨，促进大脑的新陈代谢，恢复脑细胞功能。2、多项科学实验研究表明，叶酸、维生素C维生素E维生素B12和L-色氨酸等均是人体必需的营养素和维生素，有抗氧化作用，多种维生素还能降低同型半胱氨酸水平。而高同型半胱氨酸可能通过诱发脑血管疾病、淀粉样物毒性或对神经细胞的直接毒性增加阿尔茨海默病的风险，因此降低了同型半胱氨酸水平，就等于预防了阿尔茨海默病的发生。
色氨酸：营养增补剂。抗氧化剂。色氨酸是人体重要的神经递质-5-羟色胺的前体，是人体的必需氨基酸之一；对于大脑逻辑障碍，理解力差，反应能力减退，知觉能力下降，记忆紊乱等神经紊乱官能症有很好的治疗作用。
烟酸：据8月《神经病、神经外科和神经病学杂志》（JNeurolNeurosurgPsychiatry2004；75：1093-1099）上的一项报告说，烟酸摄入量高――特别是来源于食物的――可能减小了阿兹海默症和衰老有关的认知功能下降的风险，重度烟酸缺乏可以引起痴呆。
维生素C和维生素B族：日本和美国的医学家研究认为老年痴呆症的形成可能决定于饮食内容，所以从饮食防治着手是有效的。自由基是痴呆症的祸首。现代科学证明消灭自由基的有效物质是抗氧化营养，主要有四种：维生素ｃ、维生素ｅ、β－胡萝卜素及硒。在一项为期九年的研究中，研究人员发现，长期服用抗氧化物（维生素E、C和胡萝卜素）以及维生素B族（叶酸、维生素B6及B12），其患老年痴呆症的危险要少一半，其原因就是这些维生素能够营养大脑神经递质的传递，促进大脑细胞的生长和分裂，延缓大脑萎缩的速度，减缓老人痴呆的状态。
叶酸：1）叶酸能起到营养神经的作用。充足的叶酸可以减少体内有害物质对脑神经的损伤，还有助于减少脑神经损伤造成的认知能力下降以及老年痴呆等。
2）参与氨基酸代谢，在甘氨酸与丝氨酸、组氨酸和谷氨酸、同型半胱氨酸与蛋氨酸之间的相互转化过程中充当一碳单位的载体。
3）参与血红蛋白及甲基化合物如肾上腺素、胆碱、肌酸等的合成，促进神经元信号的接收和神经递质的传递。
总之，1、从中医方面来讲，老年痴呆症与脏腑功能失调、气血阴精不足的关系十分密切。其中心肾不足、气血虚亏、阴损精衰是发病的核心，而灵芝性甘平，归心肺肝肾经，具有多脏腑补益作用，能益心气，补中，增智慧，不忘，久食轻身不老，延年益寿。
2、老年痴呆症从病理学分析是胆碱能神经元出现了淀粉样变化，直接导致神经细胞功能的衰退。另一方面也导致神经细胞分泌的胆碱酯酶神经递质减少，影响了神经信号的传递。现代研究证实，灵芝对神经系统有调节作用，具有免疫调节、增强记忆力、平衡代谢等功能，直接影响人体衰老进程，从根本上恢复神经元和神经递质的传递。
综上所述，本发明根据药食同源的道理，缓解和防治中老年人脑痴呆症（又称阿尔茨海默症），对增强和改善大脑记忆有较好的功效，其特点有以下几点：1、活血化瘀，改善微循环，保证脑细胞供血供氧量。配方中用地龙、银杏叶和三七成分，扩张血管，缓解血管痉挛，修复侧支循环，增加脑细胞供氧量，营养正常的脑细胞，修复受损的脑细胞，激活频死的脑细胞，提高细胞活跃性，恢复记忆力。
2、修复神经递质，恢复神经传递通道。多种中药成分和维生素，能够调节神经系统的代谢，增加神经的灵敏度，对中枢神经元发出的信号进行接收和传递。
3、促进能量代谢，营养大脑细胞。从中药中提取的有效成分，能促进体内各种营养的代谢和吸收，为大脑补充足够的营养物质，使大脑细胞保持完整的新陈代谢，不至于脑细胞萎缩而减少脑细胞的死亡量。
4、提高灵敏度，增强记忆力。方中益智仁粉可促进体内钙类及血浆环磷腺苷（cAMP）的合成，提高脑去甲肾上腺素(NE)、多巴胺等对情欲、感觉传递传导物质的分泌，增加神经传导速度，提高神经反应灵敏度，增强记忆力，对学习记忆障碍有改善作用。
5、抗氧化，清除自由基，延缓衰老。灵芝多糖、VC、VE对超氧阴离子自由基的产生和红细胞脂质过氧化均有抑制作用，并对羟基自由基有清除作用，减少超氧化物歧化酶样活性，是延缓衰老的重要因素。
6、提高大脑机能，改善记忆力。由于人们对素食需求量越来越多，导致摄入磷脂酰丝氨酸的数量越来越少，而磷酯酰丝氨酸是细胞的活性物质，主要存在于大脑细胞中，改善神经细胞的功能，调节神经脉冲的传导，增加脑部供血，提高大脑记忆力，与多种中药成分合用，可促使脑疲劳的恢复，平衡情绪，减少老年记忆损失。
7、激活酶系统，调理代谢。膳食补充剂加入B族维生素和氨基丁酸，调理脏腑代谢能力，B族维生素是人体内各种酶的催化剂，是人体不可缺少的物质，参与糖、蛋白质、脂肪的代谢，氨基丁酸具有重要的生理活性，能促进脑的活化性，健脑益智，延缓脑细胞的衰老，综合使用防治老年痴呆。
8、降低同型半胱氨酸水平，减少阿尔茨海默症的发生。配方中加入多种维生素，降低了血清中的同型半胱氨酸水平，减轻了动脉硬化的程度，增加了脑供血供氧量，预防和减少了老年痴呆症的发生。
本发明的有益效果是：不但是由纯植物或提取物组合而成，无毒无副作用，而且配方简单、成本低廉，效果佳。
具体实施方式
具体实施例1：一种防治老年痴呆的保健品，其配方中各组成部分的质量配比是：益智仁粉3份、地龙蛋白提取物8份、银杏叶提取物6份、灵芝提取物8份、肉桂提取物3份、磷脂酰丝氨酸3份、γ-氨基丁酸12份、L-色氨酸3份、烟酸1份、维生素C 3份、维生素E 2份、维生素B6 0.3份、维生素B12 0.1份、叶酸 0.005份。
服用方法：每日1~3次，每次1~2g。
具体实施例2：一种防治老年痴呆的保健品，其配方中各组成部分的质量配比是：益智仁粉4份、地龙蛋白提取物9份、银杏叶提取物7份、灵芝提取物9份、肉桂提取物4份、磷脂酰丝氨酸4份、γ-氨基丁酸13份、L-色氨酸4份、烟酸1.5份、维生素C 4份、维生素E 3份、维生素B6 0.4份、维生素B12 0.2份、叶酸 0.006份。
服用方法：每日1~3次，每次1~2g。
具体实施例3：一种防治老年痴呆的保健品，其配方中各组成部分的质量配比是：益智仁粉5份、地龙蛋白提取物10份、银杏叶提取物10份、灵芝提取物10份、肉桂提取物5份、磷脂酰丝氨酸5份、γ-氨基丁酸15份、L-色氨酸5份、烟酸2份、维生素C 5份、维生素E 4份、维生素B6 0.5份、维生素B12 0.25份、叶酸 0.01份。
服用方法：每日1~3次，每次1~2g。
具体实施例4：一种防治老年痴呆的保健品，其配方中各组成部分的质量配比是：益智仁粉6份、地龙蛋白提取物11份、银杏叶提取物13份、灵芝提取物11份、肉桂提取物6份、磷脂酰丝氨酸6份、γ-氨基丁酸17份、L-色氨酸6份、烟酸2.9份、维生素C 6份、维生素E 5份、维生素B6 0.6份、维生素B12 0.3份、叶酸 0.014份。
服用方法：每日1~3次，每次1~2g。
实施效果：本发明在具体的实际中的效果举例：1. 赵克闲，年龄62，性别：男。患阿兹海默症，记忆力衰退。服用本发明所述的保健品，2个月后，未见症状进一步恶化。
2.王建国，年龄74，性别：男。患阿兹海默症，记忆力衰退。服用本发明所述的保健品，1个月后，未见症状进一步恶化，并有所恢复。
总之，本发明在使用中，累计服用人数568人次，其中：目标预防老年痴呆的人群数量为：344人，持续服用本发明3~12个月，未出现发病病例；辅助治疗224人，症状缓解人数128人，症状未恶化90人，无明显效果4人。
基于以上数据可分析得出，本发明对老年痴呆病症的预防有极大的效用，对辅助治疗老年痴呆也有明显的效果。
Claims (2)
1.一种防治老年痴呆的保健品，其特征是：配方中各组成部分的质量配比是：益智仁粉3~7份、地龙蛋白8~12份、银杏叶提取物6~14份、灵芝提取物8~12份、肉桂提取物3~7份、磷脂酰丝氨酸3~7份、γ-氨基丁酸12~18份、L-色氨酸3~7份、烟酸1~3份、维生素C 3~7份、维生素E 2~6份、维生素B6 0.3~0.7份、维生素B12 0.1~0.4份、叶酸 0.005~0.015份；本发明的最终成型药剂剂型为：粉剂、片剂、胶囊。
2.根据权利要求1所述的一种防治老年痴呆的保健品，其特征是：配方中各组成部分的最佳质量配比是：益智仁粉5份、地龙蛋白10份、银杏叶提取物10份、灵芝提取物10份、肉桂提取物5份、磷脂酰丝氨酸5份、γ-氨基丁酸15份、L-色氨酸5份、烟酸2份、维生素C 5份、维生素E 4份、维生素B6 0.5份、维生素B12 0.25份、叶酸 0.01份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410506188.7A CN104258241A (zh) | 2014-09-26 | 2014-09-26 | 一种防治老年痴呆的保健品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410506188.7A CN104258241A (zh) | 2014-09-26 | 2014-09-26 | 一种防治老年痴呆的保健品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104258241A true CN104258241A (zh) | 2015-01-07 |
Family
ID=52149898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410506188.7A Pending CN104258241A (zh) | 2014-09-26 | 2014-09-26 | 一种防治老年痴呆的保健品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104258241A (zh) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105287985A (zh) * | 2015-11-27 | 2016-02-03 | 广州白云山医药集团股份有限公司白云山制药总厂 | 药物组合物在制备防治老年痴呆的药物中的应用 |
| CN105520991A (zh) * | 2015-12-09 | 2016-04-27 | 贵州神奇药物研究院 | 一种防治老年痴呆的保健品及其制备方法 |
| CN105994919A (zh) * | 2016-06-29 | 2016-10-12 | 山东润美生物科技有限公司 | 磷脂酰丝氨酸益智仁压片糖果 |
| CN106074702A (zh) * | 2016-08-12 | 2016-11-09 | 张彦优 | 一种保健品配方 |
| CN107028169A (zh) * | 2017-03-10 | 2017-08-11 | 马国标 | 一种改善记忆力的组合物及其制备方法 |
| CN107050073A (zh) * | 2017-04-27 | 2017-08-18 | 河南佳禾康生物食品科技有限公司 | 一种增强记忆、减缓大脑衰老的保健品及其制备方法 |
| CN107125768A (zh) * | 2017-05-23 | 2017-09-05 | 深圳泰乐德营养与健康有限公司 | 一种由维生素d、e和b12组成的营养素组合物 |
| CN107362245A (zh) * | 2017-07-25 | 2017-11-21 | 江西熙帝生物科技有限公司 | 一种具有抗氧化和降同型半胱氨酸的组合物 |
| CN107616506A (zh) * | 2017-09-12 | 2018-01-23 | 陈胤成 | 基于磷脂酰丝氨酸的健脑核桃油胶囊及其制备方法 |
| CN107683997A (zh) * | 2017-07-28 | 2018-02-13 | 湖州金诺康健康科技有限公司 | 一种具有改善神经细胞功能的固体饮料及其制备工艺 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943613A (zh) * | 2006-10-24 | 2007-04-11 | 北京东方兴企食品工业技术有限公司 | 一种具有健脑作用的颗粒剂 |
| CN103844271A (zh) * | 2012-12-06 | 2014-06-11 | 孙天民 | 一种防治痴呆症的营养组合剂 |
-
2014
- 2014-09-26 CN CN201410506188.7A patent/CN104258241A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943613A (zh) * | 2006-10-24 | 2007-04-11 | 北京东方兴企食品工业技术有限公司 | 一种具有健脑作用的颗粒剂 |
| CN103844271A (zh) * | 2012-12-06 | 2014-06-11 | 孙天民 | 一种防治痴呆症的营养组合剂 |
Non-Patent Citations (3)
| Title |
|---|
| 任非等: "银杏叶提取物治疗老年痴呆症", 《中国临床康复》 * |
| 吴佳: "两大帮手为大脑助力", 《生命时报》 * |
| 胡增峣等: "中药复方治疗老年痴呆的用药规律分析", 《中药药理与临床》 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105287985A (zh) * | 2015-11-27 | 2016-02-03 | 广州白云山医药集团股份有限公司白云山制药总厂 | 药物组合物在制备防治老年痴呆的药物中的应用 |
| CN105287985B (zh) * | 2015-11-27 | 2020-05-01 | 广州白云山医药集团股份有限公司白云山制药总厂 | 药物组合物在制备防治老年痴呆的药物中的应用 |
| CN105520991A (zh) * | 2015-12-09 | 2016-04-27 | 贵州神奇药物研究院 | 一种防治老年痴呆的保健品及其制备方法 |
| CN105994919A (zh) * | 2016-06-29 | 2016-10-12 | 山东润美生物科技有限公司 | 磷脂酰丝氨酸益智仁压片糖果 |
| CN106074702A (zh) * | 2016-08-12 | 2016-11-09 | 张彦优 | 一种保健品配方 |
| CN107028169A (zh) * | 2017-03-10 | 2017-08-11 | 马国标 | 一种改善记忆力的组合物及其制备方法 |
| CN107050073A (zh) * | 2017-04-27 | 2017-08-18 | 河南佳禾康生物食品科技有限公司 | 一种增强记忆、减缓大脑衰老的保健品及其制备方法 |
| CN107125768A (zh) * | 2017-05-23 | 2017-09-05 | 深圳泰乐德营养与健康有限公司 | 一种由维生素d、e和b12组成的营养素组合物 |
| CN107125768B (zh) * | 2017-05-23 | 2021-02-26 | 深圳奥萨制药有限公司 | 一种由维生素d、e和b12组成的营养素组合物 |
| CN107362245A (zh) * | 2017-07-25 | 2017-11-21 | 江西熙帝生物科技有限公司 | 一种具有抗氧化和降同型半胱氨酸的组合物 |
| CN107683997A (zh) * | 2017-07-28 | 2018-02-13 | 湖州金诺康健康科技有限公司 | 一种具有改善神经细胞功能的固体饮料及其制备工艺 |
| CN107616506A (zh) * | 2017-09-12 | 2018-01-23 | 陈胤成 | 基于磷脂酰丝氨酸的健脑核桃油胶囊及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104258241A (zh) | 一种防治老年痴呆的保健品 | |
| CN101248873A (zh) | 具有视力保护功能的饮用食品 | |
| WO2018068566A1 (zh) | 芍药内酯苷在制备改善肠道菌群系统功能的产品中的用途 | |
| US20170274032A1 (en) | Pharmaceutical compositions for treating anxiety | |
| CN103285018A (zh) | 一种双通路防治脑病的复方神经酸产品及其制备方法和应用 | |
| CN104857154A (zh) | 一种治疗“三高”症的中药组合物及其制备方法 | |
| US20200222491A1 (en) | Pharmaceutical composition for preventing and treating senile dementia and preparation method thereof | |
| CN103908539B (zh) | 一种治疗高血压的中药组合物及其制备方法及应用 | |
| Jung et al. | Weight reduction effects of yeast hydrolysate below 10 kDa on obese young women | |
| US8784804B2 (en) | Nutraceutical composition that comprises extract of andean shilajit, for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral aging | |
| CN101785813B (zh) | 一种调脂减肥的中药制剂 | |
| CN104041813A (zh) | 一种改善记忆保健品配方 | |
| CN105285977A (zh) | 一种具有抗衰老、提高免疫力功效的保健品 | |
| CN112826901A (zh) | 一种快速缓解老年性痴呆症状的药物 | |
| CN104012971A (zh) | 改善记忆力的保健食品 | |
| CN102949424A (zh) | 一种用于缓解体力疲劳的药物组合物及其制备方法 | |
| CN111346172B (zh) | 一种提高免疫力的药物组合物 | |
| WO2021085496A1 (ja) | 組成物、抗酸化剤、抗糖化剤、神経突起伸長促進剤及び認知機能改善剤 | |
| Strupler et al. | 10 Medical Issues, Pharmacology and Nutrient Interactions | |
| Mohammed et al. | The Importance of Nutritional Supplements for Athletes | |
| CN105362703A (zh) | 一种治疗原发性高血压的中药组合物及其制备方法 | |
| Farhan et al. | Complementary/combined treatment of depression in rats: Aloe Vera, fluoxetine, acupuncture. An experimental study | |
| CN117581990A (zh) | 一种提高耐力的黄芩苷组合物及其制备工艺 | |
| Belenichev et al. | Vegetable and other adaptogens with actoprotectory properties (phytodrugs and food supplements) | |
| Viyas et al. | Role of Hippophae rhamnoides L. in the Management of Depression by Regulating Hyperhomocysteinemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150107 |
|
| RJ01 | Rejection of invention patent application after publication |